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Selective serotonin 5-HT1A  
receptor biased agonists elicit 
distinct brain activation patterns:  
a pharmacoMRI study
G. Becker1,2, R. Bolbos3, N. Costes3, J. Redouté3, A. Newman-Tancredi4 & L. Zimmer1,2,3
Serotonin 1A (5-HT1A) receptors are involved in several physiological and pathological processes and 
constitute therefore an important therapeutic target. The recent pharmacological concept of biased 
agonism asserts that highly selective agonists can preferentially direct receptor signaling to specific 
intracellular responses, opening the possibility of drugs targeting a receptor subtype in specific brain 
regions. The present study brings additional support to this concept thanks to functional magnetic 
resonance imaging (7 Tesla-fMRI) in anaesthetized rats. Three 5-HT1A receptor agonists (8-OH-DPAT, 
F13714 and F15599) and one 5-HT1A receptor antagonist (MPPF) were compared in terms of influence on 
the brain blood oxygen level-dependent (BOLD) signal. Our study revealed for the first time contrasting 
BOLD signal patterns of biased agonists in comparison to a classical agonist and a silent antagonist. By 
providing functional information on the influence of pharmacological activation of 5-HT1A receptors in 
specific brain regions, this neuroimaging approach, translatable to the clinic, promises to be useful in 
exploring the new concept of biased agonism in neuropsychopharmacology.
5-HT1A receptors belong to the family of serotonin receptors, composed of 13 receptor subtypes. 5-HT1A recep-
tors are known to play a key role in serotonin neurotransmission due to their localization both as pre-synaptic 
receptors located on serotonin cell bodies in the raphe nuclei (somatodendritic receptors) and as post-synaptic 
heteroreceptors in forebrain areas that receive serotonergic projections. In such areas, 5-HT1A receptors are 
located on pyramidal and GABAergic neurons of the neocortex and limbic system1,2. Because of their distribution 
pattern and of their central role in the modulation of the serotoninergic neurotransmission, 5-HT1A receptors are 
involved in several physiological and pathological processes and constitute therefore an important therapeutic 
target for psychiatric3 and, more recently, for neurological disorders4.
Indeed, it is now well establish that 5-HT1A receptors are one of the main targets for the treatment of mood 
disorders5, with different actions that depend strongly on their localization. For example, activation of soma-
todendritic receptors by serotonin or 5-HT1A receptor agonists decreases the firing of serotonin neurons in the 
raphe, and, consequently decreases its terminal release6. This decrease is thought to be partially responsible for 
the delay in onset of the therapeutic action of selective serotonin reuptake inhibitors (SSRI) antidepressants5. A 
recent study renewed this concept, showing that expression levels of 5-HT1A somatodendritic receptors, are criti-
cally important for SSRI treatment response by controlling serotoninergic tone7. On the other hand, the activation 
of postsynaptic 5-HT1A receptors seems to be equally important for response to antidepressants5,8. In a different 
therapeutic area, 5-HT1A receptor agonism is also known as an important feature of some atypical antipsychotics 
including clozapine, aripiprazole, ziprasidone and quetiapine9–12.
Recently, 5-HT1A receptors have attracted renewed interest as possible targets in neuropharmacology. For 
example, it was described that blockade of post-synaptic 5-HT1A receptors, located on pyramidal cells, can 
improve cognition by enhancing glutamatergic transmission13. This led to clinical trials using the 5-HT1A antago-
nist lecozotan as a procognitive drug in Alzheimer’s disease14,15. Other 5-HT1A receptor ligands such as sarizotan, 
buspirone and tandospirone were shown to alleviate dyskinesia in Parkinson’s disease patients16,17. More recently, 
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it has been reported that 5-HT1A agonists are able to correct breathing dysfunction in mouse models of Rett syn-
drome opening new perspectives for treatments of this serious orphan disorder18.
Although some clinical results with older drugs acting at 5-HT1A receptors were disappointing, all these data 
suggested that appropriate targeting of 5-HT1A receptors could improve a wide range of CNS disorders if suita-
ble pharmacotherapeutics were available. However, previously-characterized drugs targeting 5-HT1A receptors 
do not exhibit an ideal profile, firstly, because of their poor selectivity with respect to other targets and, sec-
ondly, because of their lack of differentiation between the diverse sub-populations of 5-HT1A receptors that are 
expressed in different brain regions. The need for ligands that specifically target sub-populations of 5-HT1A recep-
tors encouraged the search for more selective ligands, leading to the identification of novel biased agonists at this 
target19.
Classical agonists of G protein-coupled receptors family (GPCRs), like 5-HT1A receptors, activate G proteins 
promoting the generation of second messengers such as cyclic adenosine monophosphate (cAMP), calcium, or 
phosphoinositides. Each GPCR possesses multiple transducing pathways that can elicit desirable (therapeutic) 
pharmacological effects or unwanted side effects20,21. The recent concept of “biased agonism” asserts that highly 
selective agonists can preferentially direct receptor signaling to specific intracellular responses22. 5-HT1A recep-
tors are known to interact with Gα i3 in dorsal raphe, Gα o and Gα i3 in cortex, and Gα o, Gα i1, Gα i3 and Gα z in 
hypothalamus23. Besides this regional heterogeneity in G-subtype proteins coupling, another 5-HT1A receptor 
‘downstream’ signaling response, the phosphorylation of extracellular signal-regulated kinase (ERK1/2), also 
exhibits brain region-specificity24. This opens the possibility of identifying drugs that target 5-HT1A receptors in 
specific brain regions and may therefore exhibit superior therapeutic profiles.
In this context, we characterized novel 5-HT1A agonists, namely F15599 and F13714, which have recently been 
identified as biased agonists19,25. These ligands preferentially target cortical heteroreceptors or raphe nuclei som-
atodendritic autoreceptors, respectively26–28. Although their activity has been investigated in tests of neurochem-
ical effects, immediate early gene expression, electrophysiology and behaviour, the differential influence of the 
compounds on brain region activation (i.e., functional agonism) has not previously been explored using in vivo 
brain imaging techniques. In this study, therefore, we provide, for the first time, in vivo functional data of specific 
effects of biased agonists using magnetic resonance imaging (MRI). Specifically, the activity of rat serotoninergic 
networks was investigated by a pharmacoMRI (phMRI) approach, in which 5-HT1A receptors were activated by 
acute pharmacological challenge with biased agonists. We aimed at detecting specific spatiotemporal patterns of 
brain activity induced either by F15599 (also known as NLX-101) or F13714, in comparison to the prototypical 
agonist, 8-OH-DPAT and the 5-HT1A receptor antagonist MPPF.
Results
Temporal profiles of non-corrected overall BOLD signal changes. The baseline curves were set on 
zero by definition, because of the normalization of the non-corrected overall BOLD signal. We found no signif-
icant difference in the BOLD signal after MPPF injection in comparison to the corresponding control injection 
(i.e. saline solution). Following injection of the 5-HT1A receptor agonists, we found a significant difference in 
comparison with the control conditions. Indeed, as shown in Fig. 1, there was a clear increase in the BOLD signal 
of the dorsal striatum (+ 7%, + 6% and + 6% of the basal level for 8-OH-DPAT, F13714 and F15599, respectively). 
These BOLD signal curves indicated that the drugs elicited overall BOLD effects which can then be analysed 
using procedures suited to detecting responses at a detailed neuroanatomical level, using suitable correction 
methods. In fact, the overall BOLD signal is not corrected for statistical significance of the neurovascular effects, 
over time and by comparing particular brain areas with other regions: only BOLD activation maps, as described 
below, can be used to compare the BOLD effects between molecules and brain regions.
BOLD activation maps. The comparison of activation maps generated by treatment with a 5-HT1A ligand 
minus activation maps generated by treatment with saline was calculated for each time bin [(Tn − T0)molecule 
− (Tn − T0)saline]. The results of these comparisons are shown in Figs 2–5, which show only those pixels with 
significant difference between the condition with an agonist injection versus the condition with the saline solution 
injection.
8-OH-DPAT. Numerous areas showed a progressive activation, starting from the more rostral slice, at bregma 
3.15, which revealed activated voxels in the cingulate cortex from T2 to T5 (Fig. 2). Others voxels were activated, 
primarily at T4 and T5, in the insular cortex (dorsal and ventral parts) and in the primary motor cortex. The next 
slice (bregma 2.40) displayed clusters of activated voxels in the entire prefrontal cortex (prelimbic and infralimbic 
cortices) starting from T2, as well as in the cingulate and motor cortices. The activation was still present in the 
insular cortex and reached dorsally the primary somatosensory cortex, and ventrally the orbital cortex and the 
piriform layer, the medial forebrain bundle and the olfactory tubercle. The next slice (bregma 1.65) included the 
same activated areas, and introduced striatal activation at T4 and T5. At bregma 0.90 the BOLD activation spread 
to the striatum according to a ventro-dorsal progression. Activation starts in the ventral pallidum and olfactory 
tubercle at T2, to reach progressively the entire caudate-Putamen at T5. Interestingly, the activation does not 
include the accumbens nuclei (core and shell). The activation located in the medial septum nucleus and the 
septo-hippocampus nuclei persisted until T5. The cortical activation started in the piriform layers and reached 
the somatosensory cortex. The motor and cingulate cortices were also involved starting from T2 and reach a 
maximum at T5. In the fifth slice, at bregma − 0.60, the activation pattern followed the same progression patterns. 
Activation was seen in the islands of Calleja, preoptic areas, medial forebrain bundle and olfactory tubercle, and 
then extended to the striatum. Caudate-putamen is first involved, and the activation progresses to the globus 
pallidus at T5. Cortical activations were also seen in sagittal and cingulate parts. In the medial slice of the brain, at 
bregma − 1.35, the activation started at T2 in thalamic nuclei. Striatal structures started to be involved at T2, and 
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reached a maximal activation at T5. Somatosensory, motor and cingulate cortices were more and more involved 
from T2 to T5. It is noteworthy that preoptic nuclei are still activated. At bregma − 4.35, activated voxels were 
seen in the dentate gyrus, but also in dorsal nuclei of the thalamus. This activation extended ventrally to thalamic 
area from T2 to T5. There were also activated voxels in cortical areas, mainly at T4 and T5. In the adjacent slice, at 
bregma − 5.10, activated areas are consistent with those identified in the previous section, and followed a similar 
temporal pattern. The next slice, (i.e. bregma − 6.60) had at T2 activated voxels in a part of the dentate gyrus, the 
subiculum and in posterior cortical areas. This activation spread dramatically to all layers of superior colliculus 
and to the deep mesencephalic nuclei until T5. The last slice, at bregma − 7.35, revealed a considerable activation 
in the subiculum and post-subiculum, but also in colliculus layers as well as in deep mesencephalic areas from 
T2 to T5.
MPPF. BOLD signal was significantly enhanced in only a small area of the piriform and insular cortices in the 
slice bregma − 0.60, from T1 to T5 (Fig. 3). We also noted sparse voxels activated in the cingular cortex at bregma 
− 4.35 and the hippocampus at bregma − 5.10.
F13714. In the case of F13714 minus saline contrast, the activation pattern is shown in Fig. 4. The first slice 
(bregma 3.15) exhibited only few activated voxels in cortical areas including cingulate, motor and insular cortices. 
The second slice (bregma 2.40) revealed a cortical activation at T4 and T5, mainly in the motor and cingulate 
cortices, despite a small cluster in the infralimbic cortex. This cortical activation increased in the following slice 
(bregma 1.65) involving the cingulate, motor, primary somatosensory and insular cortices. Moreover, there are 
some activated voxels in septal nuclei. The slice at bregma 0.90 showed, from T2 to T5, small areas activated in 
the lateral parts of the caudate-putamen, but also in the cingular and motor cortices and in the olfactory tract. 
There were also activated voxels in the septal nucleus from T2 to T5, as well as in the lateral parts of the cortex. 
Activation areas in the slice corresponding to bregma − 0.60 were firstly ventral, including preoptic areas, ante-
rior amygdaloid areas and ventral pallidum. Starting from T3, activation also involved cortical areas, mainly 
somatosensory, motor and cingulate cortices. The more extensive activation caused by the F13714 was in the 
slice at bregma − 1.35. At that level, the main activation was observed in thalamic nuclei, starting from T1, and 
subsequently extended ventrally. Ventral nuclei were activated from T2 to T5, including preoptic and amygdaloid 
nuclei. This slice showed also a sharp cortical activation, in all cortical areas except piriform layers. At the medial 
level (bregma − 4.35), activated areas were observed in the dentate gyrus, the median habenular nuclei and the 
Figure 1. Mean ± SEM change (%) in overall BOLD signal intensity compared to the baseline level. 
The time courses obtained from each rat, i.e. the average of all pixels from dorsal striatum ROI in individual 
datasets, were normalized by subtracting the average baseline (zero on average, by definition). Pharmacological 
challenges (mean + SEM) were carried out 72 hours after the control test, i.e. saline solution (mean–SEM). 
Upon each time course is drawn the chemical structure of the corresponding compound. (a) 8-OH-DPAT 
(n = 8). (b) MPPF (n = 6). (c) F13714 (n = 9). (d) F15599 (n = 6).
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paraventricular thalamic nuclei. Cortical activated voxels were still detectable from T3 to T5. While this cortical 
activation was reduced at the level of bregma − 5.10, from T3 to T5, the most significant activation was seen in 
the subiculum and reached the superior colliculus. In the last two slices, at level bregma − 6.60 and − 7.35, the 
activation remained in the subiculum and in the post-subiculum, respectively, from T2 to T5. At bregma − 6.60, 
it progressively expanded to layers of the colliculi, while at − 7.35, the others activated areas were located in peri-
aqueductal grey matter.
F15599. We noted, for the F15599 minus saline test, an extremely specific and limited activation (Fig. 5). The 
first rostral slice showed activated voxels in the optical cortex at T1 and T2, and some others in pre- and infral-
imbic cortices mainly at T5. The next slice (bregma 2.40) confirmed this activation while T4 and T5 time bins 
Figure 2. Areas of significant activation following i.p. injection of 8-OH-DPAT. Data are processed in 
successive 3-min blocks from onset of injection (T1) to the end of acquisition (T5). Statistically significant areas 
for each time bin, for 8 rats, using an ANOVA for 8-OH-DPAT minus saline injection (p < 0.001 uncorrected).  
Z score in colour scale, bregma coordinates on the left scale, time scale start at T1 (15 minutes after the 
beginning of the MRI session).
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displayed more activated voxels in septo-hippocampal nuclei. The cingulate cortex was clearly activated from T2 
to T5 in the slices at bregma 1.65 and 0.90, as were some voxels in median and septo-hippocampal nuclei. This 
slice also showed activated voxels in the ventral part, probably corresponding to the olfactory tract. At the coordi-
nate bregma − 0.60 and − 1.35, those preoptic nuclei were still activated. Cortical activation was observed mainly 
in several parts of the retrosplenial cortex (slices − 6.60 and − 7.35).
Summary of the results. These results show, for the first time, distinct BOLD activation patterns between 
two 5-HT1A “biased agonists”, a prototypical 5-HT1A agonist and a “silent” 5-HT1A antagonist. In the case of 
F13714 (0.04 mg/kg), activation involved a circuit composed of thalamo-cortical areas, ventral preoptic and pal-
lidum nuclei in its caudal part. In the median brain, only a small part of the hippocampus (i.e. subiculum) was 
Figure 3. Areas of significant activation following i.p. injection of MPPF. Data are processed in successive 
3-min blocks from onset of injection (T1) to the end of acquisition (T5). Statistically significant areas for each 
time bin, for 6 rats, using an ANOVA for MPPF minus saline injection (p < 0.001 uncorrected). Z score in color 
scale, bregma coordinates on the left scale, time scale start at T1 (15 minutes after the beginning of the MRI 
session).
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activated, and then the colliculus and mesencephalic nuclei. BOLD stimulation induced by F15599 (0.16 mg/kg) 
was strictly restricted to a network composed by the limbic and retrosplenial cortices, and the median septum.
On the contrary, 8-OH-DPAT (0.32 mg/kg), induced a widespread activation across the whole brain, including 
both ventral and dorsal striatum, medio-rostral hippocampus, the dorsal thalamus along the midline, and cortical 
areas (i.e. limbic, motor and somatosensory). The rostral part of the midbrain was also deeply activated. In sharp 
contrast, blockade of 5-HT1A receptors by the selective antagonist, MPPF (0.16 mg/kg), didn’t lead to any specific 
BOLD activation except for small cortical areas. Figure 6 summarizes the topography of these main networks.
Figure 4. Areas of significant activation following i.p. injection of F13714. Data are processed in successive 
3-min blocks from onset of injection (T1) to the end of acquisition (T5). Statistically significant areas for each 
time bin, for 9 rats, using an ANOVA for F13714 minus saline injection (p < 0.001 uncorrected). Z score in color 
scale, bregma coordinates on the left scale, time scale start at T1 (15 minutes after the beginning of the MRI 
session).
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Discussion
To our knowledge, this is the first in vivo imaging contribution to the pharmacological concept of biased ago-
nism. We choose to study the influence of biased agonists on functional magnetic resonance imaging (fMRI) by 
detecting with a reduced time-resolution the blood oxygen level dependent (BOLD) signal. The application of 
fMRI methods to examine the central effects of pharmacological agents used as stimuli drugs has been dubbed as 
pharmacological-MRI (phMRI)29. Briefly, the method relies on the detection of a weak NMR signal enhancement 
(around 2 to 5%) due to the decrease in concentration of deoxyhemoglobin, that is paramagnetic, within the 
activated brain zones, translating an increase of oxygen consumption. The phMRI approach therefore offers an 
in vivo whole-brain view on resulting changes in brain activity and is a non-invasive method to map 
spatio-temporal changes in neuronal activities under acute pharmacological challenge. Indeed, phMRI is a useful 
Figure 5. Areas of significant activation following i.p. injection of F15599. Data are processed in successive 
3-min blocks from onset of injection (T1) to the end of acquisition (T5). Statistically significant areas for each 
time bin, for 6 rats, using an ANOVA for F15599 minus saline injection (p < 0.001 uncorrected). Z score in 
color scale, bregma coordinates on the left scale, time scale start at T1 (15 minutes after the beginning of the 
MRI session).
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tool to study serotonin neurotransmission, for example, in animal models30, as well in humans in a translational 
manner, as suggested by the increased number of phMRI studies focused on 5-HT-modifying drugs31,32.
In the present study, pharmacological actions of the biased agonists F15599 and F13714, used at appropriate 
doses, led to the activation of very different neuronal networks.
Before discussing the results and the perspectives they open, methodological considerations about experimen-
tal procedures, data processing and interpretations should be explained. Although our study doesn’t aim to elu-
cidate the phenomena underlying neurovascular coupling33 (and particularly receptor-mediated hemodynamic 
modifications), the present protocol was designed to achieve maximal reproducibility of BOLD signal measure-
ment. First, each rat was its own control by fMRI acquisition under saline solution injection (placebo condition), 
three days before the pharmacological challenge with one of the 5-HT1A ligands. The maintenance of strictly 
comparable conditions between control and test image acquisitions allows us to avoid bias due to potential stim-
ulation of brain regions due to the venous injection of the drug samples. In any case, we made efforts to minimize 
the influence of the injections by normalizing the volume at 1ml/200g of body weight and by monitoring body 
temperature and respiration rates to ensure that there was no change in these parameters during acquisition and 
between the two conditions. It is important to mention that the use of anaesthesia, itself a neuropharmacological 
manipulation, requires careful consideration in phMRI experiments. Isoflurane is widely used in fMRI because 
it produces a stable anaesthesia over prolonged periods of time, with minimal physiological modifications34. 
Neuronal coupling can be detected at up to 2% isoflurane35, and functional connectivity remains accessible under 
isoflurane anaesthesia, although it is reduced compared to that in conscious animals36.
Another crucial issue was the choice of the doses of each 5-HT1A receptor ligand. In all cases, the tested doses of 
the 5-HT1A agonists were below those that are known to elicit hypothermia for these compounds37. Indeed, doses 
were chosen on the basis of tests reflecting behavioural and neurochemical 5-HT1A receptor targeting in vivo, and 
this at their minimal doses. For F15599, the dose of 0.16 mg/kg is known to preferentially activate cortical 5-HT1A 
receptors in microdialysis experiments, with only modest activation of 5-HT1A autoreceptors28. This is associated 
with beneficial properties on cognitive tests, reversing PCP-induced working and reference memory deficits38,39. 
Conversely, F13714 potently and preferentially activates 5-HT1A autoreceptors at the dose of 0.04 mg/kg24,26, 
an effect that is associated with memory effects (see below) and also produces potent anti-dyskinetic activity in 
rodent tests of L-DOPA-induced abnormal involuntary movements40. 8-OH-DPAT activates 5-HT1A auto and 
heteroreceptors at doses at or below 0.64 mg/kg41 so a dose of 0.32 mg/kg was selected here. It is important to note 
that, at the chosen doses, the effects of F15599 and F13714 are completely abolished by co-administration with a 
selective 5-HT1A receptor antagonist (see cited references) indicating that their actions are specifically mediated 
by 5-HT1A receptors, consistent with their known exceptional selectivity for this target in vitro27,42.
Some debate remains as to whether this is true for 8-OH-DPAT. Indeed, as discussed below, this prototypical 
5-HT1A agonist is known to interact with 5-HT7 receptors at modest doses and, possibly, 5-HT reuptake sites, in 
Figure 6. Topography of the main activated regions after injection of 5-HT1A ligands. (a) 8-OH-DPAT as a 
prototypical 5-HT1A agonist. (b) MPPF as a 5-HT1A “silent antagonist” (without any activation). (c) F13714 as 
a 5-HT1A biased agonist. (d) F15599 as a 5-HT1A biased agonist. Colours indicate the chronology of activation 
(yellow, T1; orange, T2; red, T3; purple, T4; blue, T5).
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addition to 5-HT1A receptors43. In comparison, the antagonist, MPPF, has previously been shown to block 5-HT1A 
receptors in vivo at the chosen dose of 0.16 mg/kg44,45.
Having carefully addressed the methodological challenges of the fMRI procedure, we observed, for the first 
time, differential neuronal activation maps corresponding to 5-HT1A biased agonism effects. Despite targeting 
the same 5-HT1A receptor family, each biased agonist, F15599 and F13714, elicited a BOLD effect propagating 
to different cortical and subcortical regions, consistent with their distinct targeting of 5-HT1A receptor subpop-
ulations reported previously (see discussion below). In contrast, the BOLD activations patterns of F15599 and 
F13714 were strikingly different to those obtained with 8-OH-DPAT, a prototypical 5-HT1A agonist, widely used 
in neuropharmacology. Our results revealed that 8-OH-DPAT activation spread notably in hippocampus and 
thalamus. We can interpret this large activation by the fact that 8-OH-DPAT is a mixed 5-HT1A/5-HT7 agonist46,47. 
The diffuse BOLD activation in caudal areas may be due to the presence of 5-HT7 receptors in these regions47, 
while strong activation in striatum could be explained by dopamine release induced by activation of postsynaptic 
5-HT1A receptors and by direct action of 8-OH-DPAT itself on 5-HT7 receptors. Moreover, the 8-OH-DPAT 
activation maps we obtained agree with a previous phMRI study with 5-HT7 receptor ligand reporting a similar 
BOLD activation in prefrontal cortex, striatum and thalamic areas48.
As negative pharmacological control, we used MPPF, a structural analogue of the silent antagonist WAY-
10063545. It is noteworthy that MPPF injection, at the same dose as F15599, had just a slight cortical effect, but did 
not activate any of the above areas, even at the latest time of acquisition:these results therefore support the silent 
antagonist profile of MPPF. Nevertheless, these data should be interpreted with caution, given that Canese et al. 
observed BOLD activation under antagonist challenge48. Although it is not possible to make a direct comparison 
with the study by Canese et al., due to the different MPPF concentrations used, it remains possible that a higher 
dose of MPPF could produce BOLD activation.
F15599, the first biased agonist we used, is a highly selective and efficacious 5-HT1A agonist in a variety of 
signal transduction models27. F15599 has a strong preferential activity on cortical 5-HT1A receptors, probably 
mediated through Gα i and pERK1/2 signalling pathways28,37,49. Such F15599 postsynaptic preference translates to 
behavioural manifestations, e.g. an attenuation of PCP-produced deficits of memory/cognition at the same dose 
we used herein39. Our in vivo data revealing activation of cortical networks by F15599 are in accordance with this 
“procognitive” profile.
In contrast, F13714, which also has high affinity and selectivity for 5-HT1A receptors (Ki, 0.05 nM)50, pref-
erentially activates somatodendritic 5-HT1A receptors and impairs cognitive performance in rat at low doses 
similar to the ones used here26,39,51. The present imaging data suggest that F13714’s impact on memory may be 
related to the activation of a hippocampo-striatal neuronal network. Indeed, activation of hippocampal 5-HT1A 
receptors is known to induce memory deficits, at least in the case of 8-OH-DPAT52. However, the present data 
demonstrating marked BOLD signal in striatal regions by F13714 may also provide a basis for this agonist’s potent 
anti-dyskinetic effects, recently reported in a rat model of Parkinson’s disease40.
At a neurochemical level, it may be speculated that the differential effects of F15599 and F13714 observed here 
probably involve regulation of multiple neuronal populations. For example, both GABAergic and glutamatergic 
neurons are likely to be involved in the cortical effects of F15599 observed by Llado-Pelfort et al.28 and regulation 
of serotonergic neurons and of dopamine release likely underlies the effects of F1371426,40.
Overall, it appears clear that, at the present doses, biased agonists that selectively target the same receptor 
subtype can exhibit widely divergent brain BOLD patterns, presumably because of distinct targeting of signal 
transduction pathways in different brain regions, which, in turn, can have specific haemodynamic effects. Such 
observations may have extensive implications at both a basic science level, for increased understanding of the role 
of different brain regions, and at a therapeutic level, for the development of improved drug treatments that target 
the appropriate brain regions involved in the brain disorder of interest. For example, the present data suggest that 
serotonergic drugs eliciting a BOLD signal in specific areas of the frontal cortex may be attractive candidates for 
treatment of cognitive dysfunction. In contrast, drugs targeting cortico-striatal networks-striatal networks may 
constitute effective anti-dyskinetic pharmacotherapies.
Conclusions
These present data reveal, for the first time by in vivo imaging, the specific pattern of activation of 5-HT1A biased 
agonists and their difference with a prototypical agonist, at least at the doses tested herein. These data suggest that 
phMRI imaging could make an important contribution to the in vivo characterization of novel biased agonists. 
Supplementary studies are now scheduled to expand this initial work. Firstly, a longer acquisition time would be 
interesting to determine the duration of action of the drugs for activation of different brain regions and according 
to the respective pharmacokinetics of each 5-HT1A ligand. Secondly, increased doses of the drugs will be tested in 
order to explore the extent of the dose-dependency of biased-agonist effects. Thirdly, by associating the present 
data with PET imaging of receptor occupancy, it should be possible to determine a correlation of the present 
BOLD effects with the level of 5-HT1A receptor drug-occupancy of each ligand. Finally, and thanks to the trans-
lational aspect of fMRI, this paradigm can be transferred to larger animals and, ultimately to human subjects, 
opening a new way in the investigation of biased agonists as drug candidates.
Methods
Animals and experimental procedures. Twenty-nine male Sprague-Dawley adult rats (Charles River 
laboratories, France) of 277.8 ± 19.6 g (mean at the beginning of the protocol) were used within all the exper-
iments. The animals were hosted in standard temperature and humidity conditions with a 12h/12h light/dark 
cycle. Food and water were provided ad libitum. All experiments were performed in accordance with European 
guidelines for care of laboratory animals (2010/63/EU) and were approved by the Animal Use Ethics Committee 
of the University of Lyon (Université Claude Bernard Lyon 1).
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Experimental procedures. Anesthesia was performed using an approved system (TEM Sega, Lormont, 
France). First, the animals were placed in an induction box and a mixture of 4% isoflurane (Laboratoire 
Bekamont, Boulogne Billancourt, France) and air with 30% oxygen was delivered at 1L/min flow rate.
A catheterization procedure was performed for an intra-peritoneal injection of pharmacological agents during 
the MRI acquisition. The catheter was maintained by ligation to the abdominal wall and a one meter-long tube 
was connected to carry out pharmacological agents or saline injections.
The animals were placed on prone position in a dedicated plastic holder (Bruker Biospec Animal Handling 
Systems, Germany), adapted with a stereotactic system allowing animal’s head immobilization. The anaesthesia 
was delivered via a dedicated cone mask and maintained at 2% of isoflurane during the entire MRI session. The 
body temperature was maintained at 37 ± 0.2 °C by means of a temperature-controlled water circuit integrated in 
the dedicated holder. A respiratory sensor was also placed on the animal’s abdomen allowing a continuous mon-
itoring of the respiration rate (Trigger ECG Unit RH V.0, Rapid Biomedical, Germany).
MRI Protocol. The MRI protocol was carried out on a 7-Tesla Bruker Biospec MR system (Bruker Biospin 
GbmH, Germany) equipped with a 400 mT/m maximal amplitude gradient set and controlled by a workstation 
interfaced with ParaVision5.1 software for data acquisition and post-processing (Bruker, Germany). A trans-
mitting body coil (outer diameter, 112mm and inner diameter, 72mm) and a receive-only surface coil (25 mm 
of diameter) were used for rat brain image acquisitions. A 2D anatomical T2-RARE image (Rapid Acquisition 
with Relaxation Enhancement) was obtained with the following parameters: echo time (TE): 69.1 ms, repetition 
time (TR): 5000 ms, field of view: 3 × 1.5 cm2, matrix 256 × 128 pixels, spatial resolution: 117 μ m2, RARE factor: 8, 
acquisition time: 4 minutes. Ten contiguous slices of 1.5-mm thickness were acquired, covering the whole rat brain.
To measure local cerebral hemodynamic variations during pharmacological stimulations, the BOLD 
(Blood-Oxygen-Level-Dependent) functional MRI method was employed. A T2* (Echo Planar Imaging) 
sequence was used with the following parameters: TE/TR: 25/3000 ms, matrix 128 × 64 pixels, spatial resolution: 
234 μ m2. Ten slices were acquired with the identical geometry of the anatomical T2-RARE scan that facilitated 
further region of interest (ROI) definition. Each BOLD fMRI session consisted in one series of 600 repetitions 
(scanning time of 30 minutes).
All animals were scanned under two distinct conditions: a control condition, which consisted of saline solu-
tion (NaCl 0.9%) injection, and, 72 hours later, a second challenge condition consisting of a pharmacological 
molecule injection. The 29 animals were randomly divided into 4 groups, one for each pharmacological mole-
cule used. The molecules were following 5-HT1A ligands: 8-OH-DPAT (n = 8), F13714 (n = 9), F15599 (n = 6) 
and MPPF (n = 6). The injected doses were 0.32 mg/kg for 8-OH-DPAT, 0.04 mg/kg for F13714, 0.16 mg/kg for 
F15599, and 0.16 mg/kg for MPPF. The injected volumes of the molecule and saline solutions were calibrated at 
0.5 mL per 100g of body weight. The pharmacological or saline solutions were injected 15 min after the beginning 
of the 30 min BOLD fMRI session, resulting in 300 baseline scans and 300 post-injection scans. The injections 
were carried out over a period of 30 seconds, followed by a 600 μ L saline flush.
Data Analysis
Regional time course responses. Time courses of the BOLD signal intensities were examined in the dor-
sal striata of each animal. The dorsal striata were manually delineated on T2 slices according to a rat brain atlas53 
and this for each rat of the protocol. Then, the time courses of the BOLD signal were extracted. Temporal points 
were obtained by averaging the BOLD signal intensity values through all pixels within the ROI. For each individ-
ual and anatomical ROI, baseline time points were averaged. This mean value was used to normalize the regional 
BOLD time course.
BOLD activation maps and statistics. Data were analyzed using Statistical Parametric Mapping software 
(SPM8, The Wellcome Trust Center for Neuroimaging, London, UK). Three preprocessing steps were performed: 
(1) images realignment using a spatial cross-correlation algorithm to correct possible head movements during 
acquisition, (2) spatial normalization using a standardized MRI template54, and (3) spatial smoothing using an 
isotropic Gaussian filter [1 × 1 × 1 mm]. All these preprocessing steps enabled inter-subject averaging.
For each group, a first-level analysis (intra-subject) was performed both for saline and 5-HT1A molecule con-
ditions. The 600 scans per session were divided into six time bins (Fig. 7), as suggested by McKie et al.55. The 300 
baseline scans (15 min) were defined as the first time bin (T0). The 300 post-injection scans (15 min) were divided 
Figure 7. phMRI protocol time line. The 30-min scan was divided into two 15-min sections (pre-injection 
and post-injection). T0 was the pre-injection scan and included all 300 volumes in the 15-min time bin. The 
injection scans were divided into five lots of 60 scans time bins (30 min each, T1 to T5).
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into 5 time bins of 60 scans each (T1 to T5). All six time bins were then introduced into a SPM block design using 
a General Linear Model (GLM) approach.
For both conditions (saline and molecule) of each subject, the five post-injection time bins (T1 to T5) were 
individually compared to T0 using a student t-test (p < 0.01). This first-level analysis resulted in five first-level 
parametric contrast images per subject and per condition, corresponding to contrasts [Tn − T0]condition.
Second-level (random effect) analyses were carried out to determine whether these individual contrast images 
statistically increase in a significant way at a voxel level between time bins (T0, T1, T2, T3, T4) for each mol-
ecule. This second-level used analysis of variance (ANOVA) with the times bins contrasts as between-group 
factor (molecule versus saline injections) for each time bin. This second-level ANOVA was computed for each 
group (8-OH-DPAT; MPPF; F13714; F15599) resulting in activation maps for each molecule and each time bin 
[(Tn − T0)molecule − (Tn − T0)saline]. A significant threshold was set up at p < 0.001 uncorrected.
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